Keywords: FDA, Roche, Actemra, Rheumatoid arthritis, Approval, Markets, J&J, Remicade, Amgen, Enbrel, Abbott, Humira

FDA finally approves Roche’s Actemra for moderately-to-severely active rheumatoid arthritis

Article | 11 January 2010

Print This

Coming more than a year after the US Food and Drug Administration first asked for more data on the drug ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in